一名卵巢癌患者在接受每周一次紫杉醇治疗时出现肿瘤溶解综合征。
Tumor lysis syndrome associated with weekly paclitaxel treatment in a case with ovarian cancer.
作者信息
Yahata Tetsuro, Nishikawa Nobumichi, Aoki Yoichi, Tanaka Kenichi
机构信息
Department of Obstetrics and Gynecology, Niigata University School of Medicine, 1-757 Asahimachi-Dori, Niigata, Japan.
出版信息
Gynecol Oncol. 2006 Nov;103(2):752-4. doi: 10.1016/j.ygyno.2006.06.003. Epub 2006 Jul 18.
BACKGROUND
Tumor lysis syndrome (TLS) is characterized by biochemical changes such as hyperuricemia and hyperkalemia due to rapid tumor lysis of malignant cells, usually after chemotherapy. TLS is a rare complication in nonhematological malignancies.
CASE
A 53-year-old female received intravenous weekly paclitaxel for recurrent ovarian cancer with massive ascites. Five days following the administration of paclitaxel, the patient developed TLS. She responded well to appropriate treatment with a combination of vigorous intravenous hydration, furosemide, allopurinol, and sodium bicarbonate.
CONCLUSION
This case report describes the first patient to develop TLS following paclitaxel administration for ovarian cancer. Our case is extremely exceptional because TLS occurred after the low dosage administration of paclitaxel for relatively insensitive tumor types without any risk factors.
背景
肿瘤溶解综合征（TLS）的特征是由于恶性细胞快速溶解，通常在化疗后出现高尿酸血症和高钾血症等生化变化。TLS在非血液系统恶性肿瘤中是一种罕见的并发症。
病例
一名53岁女性因复发性卵巢癌伴大量腹水接受每周一次的静脉注射紫杉醇治疗。紫杉醇给药五天后，患者发生了TLS。通过积极静脉补液、呋塞米、别嘌醇和碳酸氢钠联合进行适当治疗，她反应良好。
结论
本病例报告描述了首例在接受紫杉醇治疗卵巢癌后发生TLS的患者。我们的病例极为特殊，因为TLS发生在对相对不敏感的肿瘤类型给予低剂量紫杉醇且无任何危险因素之后。
Zotero 插件